GeneDx Q3 2026 Earnings Date & Estimates

GeneDx (NASDAQ:WGS), doing business as GeneDx, is a genomic diagnostics company that provides genetic testing and interpretation services for patients with suspected rare and inherited conditions. The company combines sequencing technologies with clinical expertise and data analysis to help healthcare professionals identify genetic causes of disease and support diagnosis, treatment planning and patient management.

GeneDx’s offerings include whole exome and whole genome sequencing, as well as targeted testing for specific genetic disorders and hereditary cancer conditions. Its services are used by physicians, hospitals, health systems and other healthcare organizations, and the company also provides educational and interpretive resources intended to help clinicians understand genetic test results.

Founded in 2000, GeneDx was initially established to focus on genetic testing for rare diseases. The business was acquired by BioReference Laboratories in 2014 and later became part of Sema4, which acquired GeneDx from OPKO Health in 2022. Sema4 subsequently changed its corporate name to GeneDx Holdings Corp. and trades on the Nasdaq under the symbol WGS.

GeneDx primarily serves the U.S. healthcare market through healthcare providers and institutions, while its genomic testing and data capabilities support research and biopharmaceutical activities. The company is led by Chief Executive Officer Katherine Stueland.